Skip to content
Aerpio Pharmaceuticals
  • Contact Us
  • Careers
  • About Aerpio
    • Management
    • Board of Directors
    • Advisory Board
  • Tie2 Pathway
    • The Basics
    • VE-PTP and Ang-2
  • Pipeline
    • AKB-9778
    • ARP-1536
    • AKB-4924
    • Clinical Trials
  • Therapeutic Areas
    • Diabetic Retinopathy
    • Wet AMD / DME
    • IBD
  • Investors
  • Publications
Aerpio Pharmaceuticals
  • Home
  • >>Investors
  • >>2016 Press Releases>>

2016 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
09/26/16Aerpio Therapeutics Initiates Phase 1a Study of AKB-4924, a First in Class Once-Daily, Orally Administered HIF-1 Stabilizer, in Development to Treat Inflammatory Bowel Disease (IBD)
... 
Printer Friendly Version
06/13/16Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial
... 
Printer Friendly Version
02/10/16Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study
... 
Printer Friendly Version
  • Print Page
  • E-mail Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • Investor Overview
  • Stock Information
    • Stock Quote & Chart
  • Press Releases
  • Events & Presentations
    • Upcoming Events
    • Archived Events
    • Presentations
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
  • Investor Resources
    • Investor FAQ
    • Information Request
    • E-mail Alerts
    • IR Contacts

© Aerpio

  • Site Map
  • Terms of Use
  • Privacy Policy
Website by Axxiem